Corvus Pharmaceuticals
CRVS
174 hedge funds and large institutions have $1.06B invested in Corvus Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 70 increasing their positions, 40 reducing their positions, and 30 closing their positions.
130% more call options, than puts
Call options by funds: $24.6M | Put options by funds: $10.7M
75% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 40
37% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 30
6% more funds holding
Funds holding: 164 → 174 (+10)
3% more capital invested
Capital invested by funds: $1.02B → $1.06B (+$33.2M)
0.78% more ownership
Funds ownership: 83.31% → 84.09% (+0.78%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.1M |
| 4 |
EP
Eversept Partners
New York
|
+$10.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$33M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$24.5M |
| 3 |
Morgan Stanley
New York
|
-$16M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$15.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.05M |
CRVS Hedge Fund Activity: Q2 2026 in Review
174 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2026, worth a combined $1.06B — up 3.2% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CRVS positions and 30 closed out — a net gain of 11 holders — while 70 added to existing stakes and 40 trimmed.
The largest buyer was BlackRock, adding an estimated $13.6M. The largest seller was Commodore Capital, exiting entirely with an estimated $33M sold.
- 174 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2026, up from 164 in Q1 2026.
- Funds reported $1.06B of Corvus Pharmaceuticals stock for Q2 2026, up 3.2% quarter-over-quarter.
- 41 funds opened new Corvus Pharmaceuticals positions in Q2 2026 and 30 closed out, a net change of +11 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $13.6M added.
- The largest Corvus Pharmaceuticals seller in Q2 2026 was Commodore Capital, an estimated $33M sold.
Based on aggregated 13F filings for Q2 2026.